Schizophrenia Clinical Trials in Los Angeles

Showing 161-180 of 204 trials

Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?

NCT01312272

Individuals with schizophrenia have been found to have deficits in social cognition, which is defined as the functions that are engaged during social interactions. Social cognition has been found to be critical in predicting multiple aspects of community functioning. There are no currently available medications that have been consistently found to improve social cognition in individuals with schizophrenia. Oxytocin functions as a neurotransmitter that is thought to be involved in multiple aspects of social behavior and related emotions. In this study, we test the hypothesis that acute administration of intranasal oxytocin will improve social cognition in individuals with schizophrenia.

Schizophrenia

VA Greater Los Angeles Healthcare System24 participantsStarted Apr 2011

Los Angeles, California, United States

COMPLETED< 1 mile

The Genetic Basis of Inherited Neurologic Deficits in People With Schizophrenia

NCT00247637

This is a study of the genetic basis of brain dysfunction in people with schizophrenia.

Schizophrenia

University of California, San Diego2,025 participantsStarted May 2003

Los Angeles, California, United States • San Diego, California, United States • Denver, Colorado, United States +4 more locations

COMPLETEDPhase 26.3 miles

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

NCT00968851

This study is being conducted to determine the safety and effect on cognitive function of two different doses of an investigational medication, EVP-6124, in individuals with schizophrenia who are on chronic stable atypical anti-psychotic therapy. In addition, behavioral and psychotic symptoms will be evaluated.

SchizophreniaCentral Nervous System DiseasesCognition

FORUM Pharmaceuticals Inc317 participantsStarted Dec 2009

Glendale, California, United States • Oceanside, California, United States • San Diego, California, United States +28 more locations

Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?

The Genetic Basis of Inherited Neurologic Deficits in People With Schizophrenia

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

Schizophrenia Trials in Other Cities

Study Evaluating Vabicaserin in Subjects With Schizophrenia

Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

A Long-Term, Open-Label, Study on Schizophrenia

Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia

Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone

Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia

Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone

Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

CAFE Comparison of Atypicals in First Episode of Psychosis

The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)

Other Conditions in Los Angeles